JP2004507460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507460A5 JP2004507460A5 JP2002501464A JP2002501464A JP2004507460A5 JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5 JP 2002501464 A JP2002501464 A JP 2002501464A JP 2002501464 A JP2002501464 A JP 2002501464A JP 2004507460 A5 JP2004507460 A5 JP 2004507460A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cop1
- use according
- medicament
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US62021600A | 2000-07-20 | 2000-07-20 | |
| PCT/US2001/002118 WO2001093893A2 (en) | 2000-06-07 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004507460A JP2004507460A (ja) | 2004-03-11 |
| JP2004507460A5 true JP2004507460A5 (enExample) | 2006-02-09 |
| JP4328090B2 JP4328090B2 (ja) | 2009-09-09 |
Family
ID=26904524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002501464A Expired - Fee Related JP4328090B2 (ja) | 2000-06-07 | 2001-01-22 | 神経細胞の保護療法におけるコポリマー１、関連ペプチドおよびポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020037848A1 (enExample) |
| EP (1) | EP1294390B1 (enExample) |
| JP (1) | JP4328090B2 (enExample) |
| KR (1) | KR20030007397A (enExample) |
| CN (1) | CN100438906C (enExample) |
| AT (1) | ATE314860T1 (enExample) |
| AU (1) | AU783031B2 (enExample) |
| CA (1) | CA2398277C (enExample) |
| CY (1) | CY1105263T1 (enExample) |
| DE (1) | DE60116467T2 (enExample) |
| DK (1) | DK1294390T3 (enExample) |
| ES (1) | ES2256200T3 (enExample) |
| IL (2) | IL150801A0 (enExample) |
| MX (1) | MXPA02007109A (enExample) |
| NZ (1) | NZ520282A (enExample) |
| WO (1) | WO2001093893A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| HUP0302333A3 (en) * | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| ES2386435T3 (es) | 2003-01-07 | 2012-08-21 | Yeda Research And Development Co., Ltd. | Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica |
| WO2005030955A1 (ja) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
| JP2007507541A (ja) * | 2003-10-03 | 2007-03-29 | ベイヒル セラピューティクス インコーポレーティッド | 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法 |
| JP5456235B2 (ja) | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
| JP4808631B2 (ja) * | 2003-12-09 | 2011-11-02 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン |
| JP5495490B2 (ja) | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
| ZA200702591B (en) | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| ES2541780T3 (es) * | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| US8378072B2 (en) | 2006-04-13 | 2013-02-19 | Declion Pharmaceuticals, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| WO2009063459A2 (en) * | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| HUE060304T2 (hu) * | 2010-01-04 | 2023-02-28 | Mapi Pharma Ltd | Glatiramer acetátot tartalmazó depó rendszer |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2014037952A1 (en) | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2022246250A1 (en) * | 2021-05-20 | 2022-11-24 | Washington University | Neuroprotective compositions and methods |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| EP1054880A1 (en) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
-
2001
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en not_active Ceased
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Ceased
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
-
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
-
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507460A5 (enExample) | ||
| Hohlfeld et al. | The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis | |
| Bakalash et al. | Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma | |
| JP2003520246A5 (enExample) | ||
| Schwartz | Macrophages and microglia in central nervous system injury: are they helpful or harmful? | |
| Mizrahi et al. | The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis | |
| US9517256B2 (en) | Vaccine and method for treatment of neurodegenerative diseases | |
| CN100438906C (zh) | 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途 | |
| JP2003532618A5 (enExample) | ||
| HK1054507B (zh) | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 | |
| Born et al. | Role of gammadelta T cells in protecting normal airway function | |
| JP2003518507A5 (enExample) | ||
| JP4542339B2 (ja) | 運動ニューロン疾患を治療するためのワクチン及び方法 | |
| CA2451521A1 (en) | Use of poly-glu, tyr for neuroprotective therapy | |
| AU2007264682B2 (en) | Method of treatment of age-related macular degeneration | |
| Jure et al. | IGF1 gene therapy reversed cognitive deficits and restored hippocampal alterations after chronic spinal cord injury | |
| He et al. | Glatiramer acetate reverses cognitive deficits from cranial-irradiated rat by inducing hippocampal neurogenesis | |
| JP5291878B2 (ja) | 治療的免疫のためのコポリマー１を含む点眼ワクチン | |
| ES2541780T3 (es) | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 | |
| von Euler Chelpin et al. | Targets and mechanisms in prevention of Parkinson's disease through immunomodulatory treatments | |
| García et al. | The severity of spinal cord injury determines the inflammatory gene expression pattern after immunization with neural-derived peptides | |
| Palumbo et al. | Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders | |
| Mantzourani et al. | Structural requirements for binding of myelin basic protein (MBP) peptides to MHC II: effects on immune regulation | |
| Wang et al. | Enhanced expression of neurotrophic factors in the injured spinal cord through vaccination with myelin basic protein-derived peptide pulsed dendritic cells | |
| JP2007511210A5 (enExample) |